Skip to main content

Voyager Therapeutics Inc

For the period ended Dec 31, 2024. Filed Mar 11, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 11, 2025

VYGR$1.99+6.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 9B. Other Information

*(c)*Director and Officer Trading Arrangements

A portion of the compensation of our directors and officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended, or the Exchange Act) is in the form of equity awards and, from time to time, directors and officers engage in open-market transactions with respect to the securities acquired pursuant to such equity awards or our other securities, including to satisfy tax withholding obligations when equity awards vest or are exercised, for diversification or other personal reasons.

Transactions in our securities by directors and officers are required to be made in accordance with our insider trading policy, which requires that the transactions be in accordance with applicable U.S. federal securities laws that prohibit trading while in possession of material nonpublic information. Rule 10b5-1 under the Exchange Act provides an affirmative defense that enables directors and officers to prearrange transactions in our securities in a manner that avoids concerns about initiating transactions while in possession of material nonpublic information.

The following table describes, for the fourth quarter of fiscal year 2024, each trading arrangement for the sale or purchase of our securities adopted or terminated by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), or a Rule 10b5-1 trading arrangement, or (2) a non-Rule 10b5-1 trading arrangement, as defined in Item 408(c) of Regulation S-K.

​​​​​​
​​Type ofNature ofDuration of TradingAggregate
​Action TakenTradingTradingTradingNumber of
Name (Title)(Date of Action)ArrangementArrangementArrangementSecurities
Nathan Jorgensen, Ph.D. (Chief Financial Officer)​Adoption (November 21, 2024)Durable Non-Rule 10b5-1 trading arrangement for sell-to-cover transactions related to restricted stock units (“RSUs”) granted on or after July 8, 2024​SaleUntil final settlement of any covered RSUIndeterminable(1)
Jacquelyn Fahey Sandell (Chief Legal Officer)Adoption (December 2, 2024)Rule 10b5-1 trading arrangement for exercises of options and sale of sharesSaleUntil January 30, 2026, or such earlier date upon which all transactions are completed or expire without execution​Up to 46,987 shares
Robin Swartz (Chief Operating Officer and Chief Business Officer)Adoption (December 5, 2024)Rule 10b5-1 trading arrangement for exercises of options and sale of sharesSaleUntil May 29, 2026, or such earlier date upon which all transactions are completed or expire without execution​Up to 70,985 shares

(1) The number of shares subject to covered RSUs that will be sold to satisfy applicable tax withholding obligations upon vesting is unknown as the number will vary based on the extent to which vesting conditions are satisfied, the market price of the company’s common stock at the time of settlement, and the potential future grant of additional RSUs subject to this arrangement. This trading arrangement, which applies to RSUs whether vesting is based on the passage of time and/or the achievement of performance goals, provides for the automatic sale of shares that would otherwise be issuable on each settlement date of a covered RSU in an amount sufficient to satisfy the applicable withholding obligation, with the proceeds of the sale delivered to the company in satisfaction of the applicable withholding obligation.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.